News

Thyrocare Technologies announced that the Board of Directors of the Company at its meeting held on 7 May 2026, inter alia, have recommended the final dividend of Rs 7 per equity Share (i.e. 70%) , subject to the approval of the shareholders.

Net profit of Thyrocare Technologies rose 117.14% to Rs 47.12 crore in the quarter ended March 2026 as against Rs 21.70 crore during the previous quarter ended March 2025. Sales rose 19.66% to Rs 223.95 crore in the quarter ended March 2026 as against Rs 187.16 crore during the previous quarter ended March 2025.For the full year,net profit rose 78.18% to Rs 163.05 crore in the year ended March 2026 as against Rs 91.51 crore during the previous year ended March 2025. Sales rose 20.61% to Rs 829.04 crore in the year ended March 2026 as against Rs 687.35 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales223.95187.16 20 829.04687.35 21 OPM %33.5330.49 -31.6127.49 - PBDT78.4660.96 29 277.62200.70 38 PBT64.4347.19 37 219.04145.44 51 NP47.1221.70 117 163.0591.51 78 Powered by Capital Market - Live News

Thyrocare Technologies will hold a meeting of the Board of Directors of the Company on 7 May 2026.

Thyrocare Technologies will hold a meeting of the Board of Directors of the Company on 28 January 2026.Powered by Capital Market - Live News

Thyrocare Technologies has allotted 10,61,07,794 equity shares of Rs 10 each under bonus issue in ratio of 2:1. Post allotment, the paid up equity share capital has increased to 15,91,61,691 equity shares of Rs 10 each. Powered by Capital Market - Live News